Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle

Cell Cycle

Volumn 12, Issue 19, 2013, Pages 3354-3363

  Risso, Guillermo ^a   Pelisch, Federico ^a,b   Pozzi, Berta ^a   Mammi, Pablo ^a   Blaustein, Matías ^a   Colman Lerner, Alejandro ^a   Srebrow, Anabella ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Akt PKB; Alternative splicing; Cell cycle; Post translational modification; Signal transduction; SUMO

Indexed keywords

FIBRONECTIN; PROTEIN BCL X; PROTEIN KINASE B; SUMO 2 PROTEIN; SUMO PROTEIN;

ACETYLATION; ALTERNATIVE RNA SPLICING; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FUNCTION; CONJUGATION; ENZYME ACTIVITY; HUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SUMOYLATION; UBIQUITINATION;

EUKARYOTA;

AKT/PKB; ALTERNATIVE SPLICING; CELL CYCLE; POST-TRANSLATIONAL MODIFICATION; SIGNAL TRANSDUCTION; SUMO;

ALTERNATIVE SPLICING; BCL-X PROTEIN; FIBRONECTINS; G1 PHASE; HEK293 CELLS; HELA CELLS; HUMANS; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION;

EID: 84886683522     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26183     Document Type: Article

References (64)

1. Hay RT. SUMO: a history of modification. Mol Cell 2005; 18:1-12; PMID:15808504; http://dx.doi.org/10.1016/j.molcel.2005.03.012 (Pubitemid 40444643)
2. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 2010; 428:133-45; PMID:20462400; http://dx.doi.org/10.1042/BJ20100158
3. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 11:861- 71; PMID:21102611; http://dx.doi.org/10.1038/nrm3011
4. Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 2013; 82:357-85; PMID:23746258; http://dx.doi.org/10.1146/annurev-biochem-061909-093311
5. Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 2001; 107:5- 8; PMID:11595179; http://dx.doi.org/ 10.1016/S0092-8674(01)00519-0 (Pubitemid 32972031)
6. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002; 108:109-20; PMID:11792325; http://dx.doi.org/10.1016/S0092-8674(01)00633-X (Pubitemid 34137016)
7. Kagey MH, Melhuish TA, Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 2003; 113:127- 37; PMID:12679040; http://dx.doi.org/10.1016/S0092-8674(03) 00159-4 (Pubitemid 36411965)
8. Kahyo T, Nishida T, Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell 2001; 8:713-8; PMID:11583632; http://dx.doi.org/10.1016/S1097-2765(01)00349-5 (Pubitemid 32946947)
9. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett 2005; 579:5007-12; PMID:16122737; http://dx.doi.org/10.1016/j.febslet.2005.07.088 (Pubitemid 41242844)
10. Hay RT. SUMO-specific proteases: a twist in the tail. Trends Cell Biol 2007; 17:370-6; PMID:17768054; http://dx.doi.org/10.1016/j.tcb.2007.08.002 (Pubitemid 47375105)
11. Cubeñas-Potts C, Matunis MJ. SUMO: a multifaceted modifier of chromatin structure and function. Dev Cell 2013; 24:1-12; PMID:23328396; http://dx.doi.org/10.1016/j.devcel.2012.11.020
12. Kadaré G, Toutant M, Formstecher E, Corvol JC, Carnaud M, Boutterin MC, Girault JA. PIAS1- mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem 2003; 278:47434-40; PMID:14500712; http://dx.doi.org/10.1074/jbc.M308562200 (Pubitemid 37523184)
13. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008; 10:654-64; PMID:18469808; http://dx.doi.org/10.1038/ncb1728 (Pubitemid 351772931)
14. Kubota Y, O'Grady P, Saito H, Takekawa M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 2011; 13:282-91; PMID:21336309; http://dx.doi.org/10.1038/ncb2169
15. Matheny RW Jr., Adamo ML. Current perspectives on Akt Akt-ivation and Akt-ions. Exp Biol Med (Maywood) 2009; 234:1264-70; PMID:19596822; http://dx.doi.org/10.3181/0904-MR-138
16. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24:7455-64; PMID:16288292; http://dx.doi.org/10. 1038/sj.onc.1209085 (Pubitemid 41637985)
17. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94:29- 86; PMID:16095999; http://dx.doi.org/10.1016/S0065-230X(05)94002-5 (Pubitemid 41202364)
18. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011; 23:1515-27; PMID:21620960; http://dx.doi.org/10.1016/ j.cellsig.2011.05.004
19. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009 (Pubitemid 46962095)
20. Santi SA, Lee H. The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol 2010; 298:C580-91; PMID:20018949; http://dx.doi.org/10.1152/ajpcell.00375.2009
21. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001; 276:31858-62; PMID:11445557; http://dx.doi.org/10.1074/jbc.C100271200
22. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB. Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem 2002; 277:38021-8; PMID:12149249; http://dx.doi.org/10.1074/jbc. M203387200 (Pubitemid 35154653)
23. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008; 27:1932- 43; PMID:18566586; http://dx.doi.org/10.1038/emboj.2008.120
24. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 2010; 5:e9646; PMID:20333297; http://dx.doi.org/10.1371/journal.pone.0009646
25. Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011; 2:467-76; PMID:21670491
26. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011; 4:ra46; PMID:21775285; http://dx.doi.org/10.1126/scisignal.2001465
27. Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, Narita M, Kohno T, Yokota J, Bohgaki M, et al. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell 2009; 17:800-10; PMID:20059950; http://dx.doi.org/10.1016/j.devcel.2009.09.007
28. Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, Kim K, Kim J, An IS, Kim J, et al. Akt is negatively regulated by the MULAN E3 ligase. Cell Res 2012; 22:873-85; PMID:22410793; http://dx.doi.org/10.1038/cr.2012.38
29. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009; 325:1134- 8; PMID:19713527; http://dx.doi.org/10. 1126/science.1175065
30. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010; 9:487-97; PMID:20081374; http://dx.doi.org/10. 4161/cc.9.3.10508
31. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012; 149:1098-111; PMID:22632973; http://dx.doi.org/10.1016/j.cell.2012.02.065
32. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29:233- 42; PMID:15130559; http://dx.doi.org/10.1016/j. tibs.2004.03.006 (Pubitemid 38591317)
33. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30:203-13; PMID:18439899; http://dx.doi.org/10.1016/j.molcel.2008.02. 024 (Pubitemid 351626686)
34. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011; 10:2218- 32; PMID:21623170; http://dx.doi.org/10.4161/cc.10.13. 16305
35. Lai VK, Ashraf M, Jiang S, Haider K. MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 2012; 11:767-77; PMID:22374674; http://dx.doi.org/10.4161/cc.11.4.19211
36. Blaustein M, Pelisch F, Coso OA, Bissell MJ, Kornblihtt AR, Srebrow A. Mammary epithelialmesenchymal interaction regulates fibronectin alternative splicing via phosphatidylinositol 3-kinase. J Biol Chem 2004; 279:21029-37; PMID:15028734; http://dx.doi.org/10.1074/jbc.M314260200 (Pubitemid 38656504)
37. Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadrana L, Sanford JR, Muschietti JP, Kornblihtt AR, Cáceres JF, et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 2005; 12:1037-44; PMID:16299516; http://dx.doi.org/10.1038/ nsmb1020 (Pubitemid 41746773)
38. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K, Chappell DS, Birnbaum MJ, Cheng JQ, Cooper DR. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 2005; 280:14302-9; PMID:15684423; http://dx.doi.org/10.1074/jbc. M411485200 (Pubitemid 40517333)
39. Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD, Chalfant CE. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 2010; 70:9185-96; PMID:21045158; http://dx.doi.org/10.1158/0008-5472.CAN-10-1545
40. White ES, Sagana RL, Booth AJ, Yan M, Cornett AM, Bloomheart CA, Tsui JL, Wilke CA, Moore BB, Ritzenthaler JD, et al. Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Exp Cell Res 2010; 316:2644- 53; PMID:20615404; http://dx.doi.org/10.1016/j. yexcr.2010.06.028
41. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA, Rosenfeld MG, et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 2012; 47:422-33; PMID:22727668; http://dx.doi.org/10.1016/j.molcel.2012.05. 014
42. Vu NT, Park MA, Shultz JC, Goehe RW, Hoeferlin LA, Shultz MD, Smith SA, Lynch KW, Chalfant CE. hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L. J Biol Chem 2013; 288:8575-84; PMID:23396972; http://dx.doi.org/10.1074/jbc. M112.443333
43. Oliva JL, Zarich N, Martínez N, Jorge R, Castrillo A, Azañedo M, García-Vargas S, Gutiérrez-Eisman S, Juarranz A, BoscáL, et al. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras. J Biol Chem 2004; 279:33480-91; PMID:15181015; http://dx.doi.org/10.1074/jbc.M404058200 (Pubitemid 39062997)
44. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-44; PMID:17611497; http://dx.doi.org/10.1038/nature05933 (Pubitemid 47123510)
45. Massiello A, Salas A, Pinkerman RL, Roddy P, Roesser JR, Chalfant CE. Identification of two RNA cis-elements that function to regulate the 5' splice site selection of Bcl-x pre-mRNA in response to ceramide. J Biol Chem 2004; 279:15799-804; PMID:14734550; http://dx.doi.org/10.1074/jbc. M313950200 (Pubitemid 38509266)
46. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 2007; 176:929-39; PMID:17371836; http://dx.doi.org/10.1083/jcb.200701005 (Pubitemid 46506967)
47. Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, Chabot B. Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther 2008; 7:1398-409; PMID:18566212; http://dx.doi.org/10.1158/1535- 7163.MCT-08-0192
48. Wang Q, Silver PA. Genome-wide RNAi screen discovers functional coupling of alternative splicing and cell cycle control to apoptosis regulation. Cell Cycle 2010; 9:4419-21; PMID:21088477; http://dx.doi.org/10.4161/cc.9.22.14051
49. Chang WH, Liu TC, Yang WK, Lee CC, Lin YH, Chen TY, Chang JG. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res 2011; 71:383-92; PMID:21224352; http://dx.doi.org/10.1158/0008-5472.CAN-10-1037
50. Shkreta L, Michelle L, Toutant J, Tremblay ML, Chabot B. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem 2011; 286:331-40; PMID:20980256; http://dx.doi.org/10.1074/ jbc. M110.162644
51. Apostolatos A, Song S, Acosta S, Peart M, Watson JE, Bickford P, Cooper DR, Patel NA. Insulin promotes neuronal survival via the alternatively spliced protein kinase CDII isoform. J Biol Chem 2012; 287:9299- 310; PMID:22275369; http://dx.doi.org/10.1074/jbc.M111.313080
52. Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K, Wang P. Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res 2013; PMID:23884910; http://dx.doi.org/10.1158/0008-5472.CAN-13-0538
53. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, Liu X, Cheng J, et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 2012; 3:911; PMID:22713753; http://dx.doi.org/10.1038/ncomms1919
54. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013; 341:395- 9; PMID:23888040; http://dx.doi.org/10. 1126/science.1236188
55. González-Santamaría J, Campagna M, Ortega- Molina A, Marcos-Villar L, de la Cruz-Herrera CF, González D, Gallego P, Lopitz-Otsoa F, Esteban M, Rodríguez MS, et al. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis 2012; 3:e393; PMID:23013792; http://dx.doi.org/10.1038/cddis.2012.135
56. Psakhye I, Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell 2012; 151:807-20; PMID:23122649; http://dx.doi.org/10.1016/j.cell.2012.10.021
57. Hara S, Nakashiro K, Goda H, Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun 2008; 370:123-8; PMID:18355439; http://dx.doi.org/10.1016/j. bbrc.2008.03.042
58. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20:6877-88; PMID:11726523; http://dx.doi.org/10.1093/emboj/20.23.6877 (Pubitemid 33134217)
59. Cheng J, Kang X, Zhang S, Yeh ET. SUMOspecific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007; 131:584- 95; PMID:17981124; http://dx.doi.org/10.1016/j.cell.2007.08.045 (Pubitemid 350007694)
60. Kang X, Qi Y, Zuo Y, Wang Q, Zou Y, Schwartz RJ, Cheng J, Yeh ET. SUMO-specific protease 2 is essential for suppression of polycomb group proteinmediated gene silencing during embryonic development. Mol Cell 2010; 38:191-201; PMID:20417598; http://dx.doi.org/10.1016/j.molcel.2010.03.005
61. Cazalla D, Sanford JR, Cáceres JF. A rapid and efficient protocol to purify biologically active recombinant proteins from mammalian cells. Protein Expr Purif 2005; 42:54-8; PMID:15878828; http://dx.doi.org/10.1016/j.pep.2005. 03.035 (Pubitemid 40793393)
62. Pelisch F, Gerez J, Druker J, Schor IE, Muñoz MJ, Risso G, Petrillo E, Westman BJ, Lamond AI, Arzt E, et al. The serine/arginine-rich protein SF2/ASF regulates protein sumoylation. Proc Natl Acad Sci U S A 2010; 107:16119-24; PMID:20805487; http://dx.doi.org/10.1073/pnas.1004653107
63. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT. Detection of protein SUMOylation in vivo. Nat Protoc 2009; 4:1363-71; PMID:19730420; http://dx.doi.org/10.1038/nprot.2009.128
64. Cramer P, Cáceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE, Kornblihtt AR. Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol Cell 1999; 4:251- 8; PMID:10488340; http://dx.doi.org/10.1016/S1097-2765(00) 80372-X (Pubitemid 29456893)